Compare Neurocrine Biosciences Inc (NBIX) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nerdwallet Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B), while Nerdwallet Inc trades at $9.79 (market cap $625.17M). The key difference: Neurocrine Biosciences Inc is far larger — about 23× Nerdwallet Inc's market cap, and Nerdwallet Inc is more actively traded (1,321,316 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Nerdwallet Inc for 45 Days on average.
| NBIX | NRDS | |
|---|---|---|
Market Cap | $14.36B | $625.17M |
Volume | 1,237,180 | 1,321,316 |
Sector | Health | Media |
52-Week High | $185.50 | $15.93 |
52-Week Low | $123.10 | $7.58 |
Typical Hold Time | 23 Days | 45 Days |
Enterprise Value | $14.37B | $539.47M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
NerdWallet (NRDS) trades at $9.82, up 8.04% with strong technical momentum. The company shows improving fundamentals with 2025 revenue reaching $836.6M and net income of $48.7M, representing a 5.82% margin. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed estimates. Valuation metrics appear attractive with P/E of 10.87 and P/S of 0.81. Analyst sentiment remains positive with 66.7% buy ratings and technical indicators signaling bullish momentum.
The outlook remains constructive as NerdWallet demonstrates revenue growth acceleration and margin expansion. Key risks include organic search pressure in credit card products and macroeconomic sensitivity. With strong cash flow generation and institutional support, the stock offers growth potential at reasonable valuations, though investors should monitor competitive pressures and execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
